Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Bioequivalence Study of Valsartan / Amlodipine From Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland) (ABSVAFVATVAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04085627
Recruitment Status : Active, not recruiting
First Posted : September 11, 2019
Last Update Posted : September 11, 2019
Sponsor:
Information provided by (Responsible Party):
Second Affiliated Hospital of Wenzhou Medical University

Brief Summary:
Comparative randomized, single dose, three periods, three-way crossover open-label study to determine the bioequivalence of Valsartan and Amlodipine Tablets (Hua yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland).

Condition or disease Intervention/treatment Phase
Healthy Drug: Valsartan and Amlodipine Tablets Phase 1

Detailed Description:

Primary Pharmacokinetic Parameters: Cmax, Area under cover (AUC0→t and AUC0→∞ ) .Secondary Pharmacokinetic Parameters: tmax and t1/2. The method of judging bioequivalence of three-cross-section repeating experiment design: first of all, the calculation of the SWR of the AUC and Cmax, if SWR≥0.294, the use of RSABE analysis; if Swr<0.294, the average Bioequivalence analysis method with Non-scale (bioequivalence limit is 80%~125 %).

A comprehensive final report will be issued upon the completion of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comparative Open-label,Randomized, Fasting/Fed, Single Dose, Three-way Crossover Bioequivalence Study of Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerland)
Actual Study Start Date : October 8, 2018
Actual Primary Completion Date : November 28, 2018
Estimated Study Completion Date : December 26, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: T Test
Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
Drug: Valsartan and Amlodipine Tablets
1 tablet contains Valsartan 80mg& Amlodipine 5mg

Active Comparator: R Reference
Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
Drug: Valsartan and Amlodipine Tablets
1 tablet contains Valsartan 80mg& Amlodipine 5mg




Primary Outcome Measures :
  1. Bioequivalence based on Cmax [ Time Frame: Up to 96 hours post dose in each treatment period ]
  2. Bioequivalence based on AUC parameters [ Time Frame: Up to 96 hours post dose in each treatment period ]

Secondary Outcome Measures :
  1. Number of subjects with adverse events (AE)s [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Safety and tolerability parameters will include recording of AEs(blood biochemistry, urine routine examination, electrocardiograph, etc.)

  2. blood pressure [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Vital sign measurement will include blood pressure

  3. pulse rate [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Vital sign measurement will include pulse rate

  4. respiration rate [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Vital sign measurement will include respiration rate

  5. ear temperature [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Vital sign measurement will include ear temperature

  6. complete blood count [ Time Frame: Up to 96 hours post dose in each treatment period ]
    Clinical laboratory tests will include CBC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or non-pregnant non-lactating female, age 18 to 45 years, including the critical value.
  • Male weight ≥ 50kg, female weight ≥ 45kg, body mass index (BMI) between 19 and 28kg / m2, including the critical value.
  • Good health, no heart, liver, kidney, digestive tract, nervous system, mental disorders and metabolic disease history.
  • Sign informed consent prior to the test and fully understand the contents, process and possible adverse reactions, and be able to communicate well with the researcher.

Exclusion Criteria:

  • Any clinical trials in the 90 days prior to the trial, or other clinical trials planned for the duration of the trial.
  • Underwent major surgery within 90 days of the trial or planned to undergo surgery within 3 months of the trial.
  • Blood loss or blood donation over 300mL in the 90 days before the test.
  • Esophageal reflux, stomach bleeding or peptic ulcer disease in the 180 days prior to the test, heartburn occurs more than once a week, or any surgical procedure that may affect drug absorption (E.G. cholecystectomy).
  • Persons with specific allergies (asthma, urticaria, eczema, etc.) or allergies (such as those who are allergic to two or more medications, food or pollen), or are known to be allergic to the ingredients * or analogues of the drug.

    • The main components of the trial preparation: valsartan, benzene sulfonic acid amlodipine, microcrystalline cellulose, crosslinked povidone, crosslinked carboxymethyl cellulose sodium, silica, magnesium stearate, hydroxypropyl methyl cellulose, iron oxide yellow, polyethylene glycol, talc, Titanium dioxide; Reference Preparation main components: valsartan, amlodipine, microcrystalline cellulose, cross-linked povidone, silica, Magnesium stearate, hydroxypropyl methyl cellulose, iron oxide yellow, polyethylene glycol, talcum powder, Titanium Dioxide.
  • Use of any medication within 28 days of the trial, including prescription, over- the-counter, and/or alternative medications (such as medicinal herbs, herbal medicines, hemostasis and blood-activating plants or health supplements), and the use of hormonal contraceptives or vaccines.
  • A history of psychotropic substance abuse.
  • Urine screening Positive.
  • The average daily smoking was over 3 in the 90 days prior to the trial, alcohol consumption, women drinking more than 7 cups per week for 28 days or more than 14 cups per week for men (1 cups of =150ml wine =360ml Beer =45ml spirits).
  • Alcohol expiratory test Positive.
  • Body temperature (ear Temperature) ≥37.5℃, breathing is obviously abnormal and the researchers believe that it is not suitable to participate in the test, sitting systolic pressure >140mmhg or <100mmhg, sitting diastolic pressure >90mmhg or <60mmhg, sitting pulse 50 times/minute or > 100 Times/minute.
  • Human immunodeficiency virus antibody (HIV-Ab), hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum antibody (TP) Positive.
  • Special dietary requirements, No uniform diet during the trial.
  • Subjects refused to comply with the drug before 48h banned caffeine, alcohol, grapefruit beverages and food (including tea, chocolate, coffee, coke, etc.).
  • Participants with a companion refused to use effective contraceptive measures within 180 days of screening to the completion of the test, as detailed in Appendix 2.
  • Female subjects were tested positive for blood/urine pregnancy.
  • Persons with impaired renal function, or who have suffered from urinary system disease.
  • A History of orthostatic hypotension.
  • fainting during venipuncture, dizzy blood and venous blood collection difficult person.
  • The physical examination was obviously abnormal and the researchers found it inappropriate to participate in the trial.
  • There was a significant abnormality in the ECG test and the researchers found it inappropriate to Participate.
  • Blood biochemistry, blood routine, urine routine examination had the obvious abnormality and the researcher thought that was not suitable to participate in the experiment.
  • Subjects may not be able to complete this study or other researchers ' judgment for other reasons. Note: the exclusion criteria in 1th, 2, 3, 4, 6, 9 in the time are from the first 1 days before the administration of the Calculation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04085627


Locations
Layout table for location information
China, Zhejiang
The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study
Wenzhou, Zhejiang, China, 325000
Sponsors and Collaborators
Second Affiliated Hospital of Wenzhou Medical University
  Study Documents (Full-Text)

Documents provided by Second Affiliated Hospital of Wenzhou Medical University:
Study Protocol  [PDF] October 1, 2018


Layout table for additonal information
Responsible Party: Second Affiliated Hospital of Wenzhou Medical University
ClinicalTrials.gov Identifier: NCT04085627     History of Changes
Other Study ID Numbers: 2018-10-17
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: September 11, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Amlodipine
Valsartan
Amlodipine, Valsartan Drug Combination
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists